Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Unilabs and Diagnoplex SA Announce the Swiss Market Launch of Colox

Published: Saturday, March 01, 2014
Last Updated: Saturday, March 01, 2014
Bookmark and Share
A non-invasive colon cancer screening test.

Unilabs and Diagnoplex SA have announced the Swiss market launch of Colox®, a non-invasive screening test for colorectal cancer.

Colox® is offered as a service by Unilabs’ clinical diagnostic service laboratories in Switzerland. Additional countries within Unilabs’ network of laboratories are planned to follow in 2014.

The novel Colox® test can detect colorectal cancer from a routine blood sample through all stages of disease, with a particular focus on early stages, where the prognosis is optimal. The test is based on quantifying a unique 29 biomarker molecular signature using quantitative RT-PCR.

The effectiveness of Colox® was confirmed in a series of prospective clinical studies. Colorectal cancer screening guidelines indicate that women and men at average risk should be offered screening for colorectal cancer and adenomatous polyps beginning at age 50 years.

‘We are proud to offer this important new option to efficiently screen for colorectal cancer, the second most important cancer in terms of mortality in developed countries’ comments Stavros Therianos, CEO of Diagnoplex SA and adds ‘our goal is now to make the test available to as many individuals at risk as possible. In parallel with this robust commercialization effort, we are looking to raise the additional funds necessary to perform complementary clinical studies leading to a full reimbursement of Colox®. To this end, we are open to discussion with interested parties’.

Alain Cahen, Unilabs’ Managing Director in Switzerland, said: ‘It is a great success to announce that Colox® is now produced by Unilabs. We have prepared a distribution strategy and a communication campaign that will reach doctors as of March. This campaign will include information regarding the logistics and availability of Colox® in the different regions of Switzerland, including explanatory brochures for the doctors and for the individuals at risk’.

Thierry Mauvernay, Delegate of the Board of Debiopharm Group - a lead investor in Diagnoplex - agreed, adding: ‘We believe that the Colox® test offers a much better and easier solution for patients than existing alternatives. As such we believe that the availability of Colox® will help increase the early detection of this important cancer, allowing treatment at an earlier stage where there is a much better chance of success’.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
Dormant Viral Genes May Awaken to Cause ALS
NIH human and mouse study may open an unexplored path for finding treatments.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Five Genetic Regions Implicated In Cystic Fibrosis Severity
An international consortium of researchers conducted the largest-ever CF genome-wide analysis to find new therapeutic targets.
Greater Understanding Of Polycystic Ovary Syndrome
A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
New Autism Genes Are Revealed in Largest-Ever Study
Work draws more detailed picture of genetic risk, sheds light on sex differences in diagnosis.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Genetic Adaptations to Diet and Climate
Researchers found genetic variations in the Inuit of Greenland that reflect adaptations to their specific diet and climate.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos